ProCE Banner Activity

Immunogenomic Determinants of Response and Survival to PD-1 Blockade in Advanced Clear Cell RCC

Slideset Download
Conference Coverage
PBRM1 mutations and del(9p21.3) associated with outcomes in advanced clear cell RCC treated with immune checkpoint inhibitors.

Released: June 08, 2020

Expiration: June 07, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono